Economic analysis in admitted patients with acute exacerbation of chronic obstructive pulmonary disease

Chinese Medical Journal

Volumn 121, Issue 7, 2008, Pages 587-591

  Chen, Ya Hong ^a   Yao, Wan Zhen ^a   Cai, Bai Qiang ^b   Wang, Hong ^c   Deng, Xiao Mei ^d   Gao, Hui Li ^a   Huang, Jia Sheng ^a   Wang, Xin Mao ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d Beijing Haidian Hospital   (China)

Author keywords

Acute exacerbation; Chronic obstructive pulmonary disease; Cost analysis

Indexed keywords

ANTIBIOTIC AGENT; CARBON DIOXIDE; CORTICOSTEROID; OXYGEN;

ADULT; AGE; AGED; ARTICLE; ARTIFICIAL VENTILATION; CARBON DIOXIDE TENSION; CEREBROVASCULAR DISEASE; CHINA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COR PULMONALE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG USE; ECONOMIC EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITAL BED UTILIZATION; HOSPITALIZATION COST; HUMAN; HYPERTENSION; INTENSIVE CARE UNIT; KIDNEY FAILURE; LABORATORY TEST; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OXYGEN TENSION; OXYGEN THERAPY; PH; POSITIVE END EXPIRATORY PRESSURE; PROGNOSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; SYSTEMIC THERAPY; TREATMENT DURATION; CLINICAL TRIAL; ECONOMICS; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY;

AGED; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES;

EID: 46449105594     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200804010-00003     Document Type: Article

References (13)

1. Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, treatment and prevention of chronic obstructive pulmonary disease (2006). (http://www.goldcopd.com)
2. Miravitlles M, Murio C, Guerrero T, Gisbert R, DAFNE study group. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.
3. Yao WZ, Zhu H, Shen N, Han X, Liang YJ, Zhang LQ, et al. Epidemiological data of chronic obstructive pulmonary disease in Yanqing county in Beijing. J Peking Univ (Health Sciences) (Chin) 2005; 37: 121-125.
4. Chinese Medical Association Respiratory Disease Division Chronic Obstructive Pulmonary Disease Study Group. Chronic obstructive pulmonary disease diagnosis and treatment guidelines (2007 revised edition). Chin J Tuberc Respir Dis (Chin) 2007; 30: 8-17.
5. Anzueto A. Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 554-564.
6. FitzGerald JM, Haddon JM, Bradly-Kennedy C, Kuramoto L, Ford GT, RUSIC Study Group. Resource use study in COPD (RUSIC): a prospective study to quantify the effects of COPD exacerbations on health care resource use among COPD patients. Can Respir J 2007; 14: 145-152.
7. Simoens S, Decramer M. Pharmacoeconomics of the management of acute exacerbations of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2007; 8: 633-648.
8. Schermer TR, Saris CG, van den Bosch WJ, Chavannes NH, van Schayck CP, Dekhuijzen PN, et al. Exacerbations and associated healthcare cost in patients with COPD in general practice. Monaldi Arch Chest Dis 2006; 65: 133-140.
9. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prütz C, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96: 700-708.
10. Dusser D, Bravo ML, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-555.
11. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med 2005; 143: 317-326.
12. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
13. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003, 21: 74-81.